首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1517630

去氧腎上腺素藥物市場 - 副產品（片劑、糖漿、眼藥水）、給藥途徑（口服、腸胃外）、適應症（感冒、鼻減充血、過敏反應）、配銷通路（醫院、零售和在線） - 2024 年全球預測 - 2032

Phenylephrine Drugs Market - By Product (Tablets, Syrup, Eye Drops), Route of Administration (Oral, Parenteral), Indication (Cold, Nasal Decongestion, Allergic Reaction), Distribution Channel (Hospital, Retail, & Online) - Global Forecast 2024 - 2032

出版日期: 2024年04月23日 | 出版商:

Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於全球過敏性鼻炎、感冒和鼻竇炎盛行率不斷上升，預計去氧腎上腺素藥物市場規模在 2024 年至 2032 年間將以 6.6% 的複合年成長率成長。根據世界過敏組織的數據，過敏性鼻炎影響超過 4 億人，成人盛行率在 10% 至 30% 之間，兒童盛行率超過 40%。由於城市化、污染和氣候變遷等因素，這些情況變得更加普遍，對有效減充血劑的需求不斷增加。

去氧腎上腺素因其緩解鼻腔和鼻竇充血的功效而被廣泛用於非處方藥 (OTC)，使其成為製藥行業的主要產品。尋求立即緩解充血症狀的消費者也更喜歡這些藥物，因為它們起效迅速且無需處方即可獲得。製藥公司正在投資研發活動，以提高去氧腎上腺素產品的功效、安全性和患者依從性。這包括創建緩釋製劑、與其他活性成分的聯合療法以及新穎的遞送系統，例如鼻噴劑和吸入器。衛生當局的監管批准和認可確保去氧腎上腺素仍然是值得信賴和廣泛使用的藥物，進一步刺激市場成長。

本產業分為產品類型、給藥途徑、適應症、配銷通路和地區。

根據產品類型，糖漿領域的去氧腎上腺素藥物市場價值預計在 2024 年至 2032 年期間將大幅複合年成長率。這一成長得益於消費者和醫療保健提供者對治療充血的廣泛接受和偏好，特別是在兒科和老年人群中。糖漿劑提供了一種可口且易於服用的片劑和膠囊替代品，使其成為吞嚥藥片有困難的兒童和老年患者的理想選擇。液體形式還可以實現精確劑量，這對於敏感人群的安全有效治療至關重要。

就適應症而言，預計到 2032 年，過敏反應領域的去氧腎上腺素藥物產業將錄得可觀的成長率。隨著越來越多的人經歷季節性過敏、過敏性鼻炎和其他過敏性疾病，對可靠的減充血劑來快速緩解的需求不斷增加。其可及性和有效性也使得基於去氧腎上腺素的產品在治療過敏症狀方面很受歡迎，從而推動了細分市場的成長。

亞太地區去氧腎上腺素藥物產業預計在預測期內呈現顯著的複合年成長率。這是由於城市化進程的不斷加速和相關污染水平的提高，導致呼吸道和過敏性疾病的發生率更高。中國、印度和日本等國家製藥業的強勁成長促進了去氧腎上腺素藥物的廣泛供應和生產。政府改善醫療基礎設施的措施和自我藥療的上升趨勢將進一步促進區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 呼吸道疾病發生率上升
  - 藥物輸送系統的進展
  - 擴大轉向非鎮靜減充血劑
  - 醫療保健支出不斷成長
- 產業陷阱與挑戰
  - 與偽麻黃鹼相比功效有限
  - 輕鬆取得替代藥物
成長潛力分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀錶板

第 5 章：市場估計與預測：按產品類型，2018 年 - 2032 年

主要趨勢
平板電腦
糖漿
眼藥水
其他產品類型

第 6 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

主要趨勢
口服
注射用
其他給藥途徑

第 7 章：市場估計與預測：按指標分類，2018 年 - 2032 年

主要趨勢
寒冷的
鼻腔減充血
過敏反應
眼部疾病
其他適應症

第 8 章：市場估計與預測：按配銷通路，2018 年 - 2032 年

主要趨勢
醫院藥房
藥局和零售藥局
網路藥局

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Novartis AG
Perrigo Company PLC
Johnson & Johnson Consumer Inc. (Kenvue Inc.)
Proctor & Gamble Co.
Pfizer, Inc.
Foundation Consumer Brands LLC
Mylan N.V.
Torrent Pharmaceuticals, Inc.
GlaxoSmithKline PLC
Bayer AG

簡介目錄

Product Code: 9161

Phenylephrine drugs market size is anticipated to register 6.6% CAGR between 2024 and 2032, driven by the increasing prevalence of allergic rhinitis, colds, and sinusitis worldwide. As per World Allergy Organization, allergic rhinitis affects over 400 million individuals, with prevalence rates ranging from 10% to 30% among adults and exceeding 40% among children. As these conditions become more common due to factors, such as urbanization, pollution, and changing climates, the demand for effective decongestants is rising.

Phenylephrine is widely used in over the counter (OTC) medications for its efficacy in relieving nasal and sinus congestion, making it a staple in the pharmaceutical industry. Consumers seeking immediate relief from congestion symptoms also prefer these drugs due to their rapid action and availability without prescription. Pharmaceutical companies are investing in R&D activities to enhance the efficacy, safety, and patient compliance of phenylephrine products. This includes the creation of sustained-release formulations, combination therapies with other active ingredients, and novel delivery systems, such as nasal sprays and inhalers. Regulatory approvals and endorsements by health authorities are ensuring that phenylephrine remains a trusted and widely used drug, further stimulating the market growth.

The industry is classified into product type, route of administration, indication, distribution channel, and region.

Based on product type, the phenylephrine drugs market value from the syrup segment is slated to witness substantial CAGR during 2024-2032. The growth is favored by the widespread acceptance and preference among both consumers and healthcare providers for treating congestion, particularly in pediatric and geriatric populations. Syrups offer a palatable and easy-to-administer alternative to tablets and capsules, making them ideal for children and elderly patients who may have difficulty swallowing pills. The liquid form also allows precise dosing, which is crucial for safe and effective treatment in sensitive groups.

In terms of indication, the phenylephrine drugs industry from the allergic reaction segment is predicted to record decent growth rate through 2032. This is influenced by the rising prevalence of allergies and related symptoms, such as nasal congestion and sinus pressure. As more individuals experience seasonal allergies, allergic rhinitis, and other allergic conditions, there is an increasing demand for reliable decongestants to provide quick relief. The accessibility and effectiveness also makes phenylephrine-based products popular for managing allergy symptoms, driving segment growth.

Asia Pacific phenylephrine drugs industry is poised to depict notable CAGR over the forecast period. This is attributed to the increasing urbanization and associated pollution levels, which contribute to higher incidences of respiratory and allergic conditions. The robust growth of the pharmaceutical industry in countries, such as China, India, and Japan are facilitating the widespread availability and production of phenylephrine drugs. Government initiatives to improve healthcare infrastructure and the rising trend of self-medication will further bolster the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of respiratory diseases
  - 3.2.1.2 Advancement in drug delivery system
  - 3.2.1.3 Increase in shift towards non-sedating decongestants
  - 3.2.1.4 Growing healthcare expenditure
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited efficacy compared to pseudoephedrine
  - 3.2.2.2 Easy availability of alternative drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Million)

5.1 Key trends
5.2 Tablets
5.3 Syrups
5.4 Eye drops
5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Cold
7.3 Nasal decongestion
7.4 Allergic reaction
7.5 Eye disease
7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Drug stores & retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa